SCHEMBL4770355

SCHEMBL4770355

COc1ccc(C#Cc2ccccc2OC)c(C=O)c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.53
CYP1A2 P05177 5/20 0.49
LMNA P02545 1/20 0.49
CYP2C9 P11712 1/20 0.49
CYP2C19 P33261 1/20 0.49
ERN1 O75460 6/20 0.47
CYP1A1 P04798 4/20 0.45
CYP1B1 Q16678 4/20 0.45
TRIM24 O15164 1/20 0.44
TYR P14679 1/20 0.44
TRIM33 Q9UPN9 1/20 0.44
DHFR P00374 1/20 0.41
TLR2 O60603 1/20 0.41
TLR1 Q15399 1/20 0.41
TLR6 Q9Y2C9 1/20 0.41
JUN P05412 1/20 0.40
NFKB1 P19838 1/20 0.40
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6358014 0.88 ALDH1A1 (0.43) ALDH1A1CYP1A2LMNACYP2C9CYP2C19
SCHEMBL4765815 0.84 ERN1 (0.49) ALDH1A1CYP1A2LMNACYP2C9CYP2C19
SCHEMBL9881727 0.80 ERN1 (0.51) ALDH1A1CYP1A2LMNACYP2C9CYP2C19
SCHEMBL30022461 0.75 CA1 (0.60) ALDH1A1LMNAMEN1KMT2AL3MBTL1
SCHEMBL4214499 0.75 CA1 (0.60) ALDH1A1LMNAMEN1KMT2AL3MBTL1
SCHEMBL22685386 0.74 ERN1 (0.56) ALDH1A1CYP1A2LMNACYP2C9CYP2C19
SCHEMBL584391 0.74 ERN1 (0.56) ALDH1A1CYP1A2CYP2C19ERN1TRIM24
SCHEMBL6358019 0.74 ERN1 (0.46) ALDH1A1ERN1TRIM24TYRTRIM33
SCHEMBL312237 0.74 ALDH1A1 (0.53) ALDH1A1CYP1A2LMNACYP2C9CYP2C19
SCHEMBL30134856 0.74 ALDH1A1 (0.53) ALDH1A1CYP1A2LMNACYP2C9CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1020445-B1 FUSED PYRIDINE DERIVATIVES EISAI R&D MAN CO LTD (JP) 2008-08-13 EP disclosed
EP-1020445-B1 FUSED PYRIDINE DERIVATIVES EISAI R&D MAN CO LTD (JP) 2008-08-13 EP disclosed
US-6875761-B2 Certain 1,3-disubstituted isoquinoline derivatives EISAI CO., LTD. (JP) 2005-04-05 US disclosed
US-20040204421-A1 Certain 1,3-disubstituted isoquinoline derivatives EISAI CO., LTD. 2004-10-14 US disclosed
US-6790844-B2 MUSCLE RELAXANTS; ANTISEROTONINE AGENT EISAI CO., LTD (JP) 2004-09-14 US disclosed
US-20020013460-A1 Condensed pyridine compound EISAI CO., LTD 2002-01-31 US disclosed
US-6340759-B1 ANTISPASMODIC AGENTS EISAI CO., LTD. (JP) 2002-01-22 US disclosed
EP-1020445-A1 FUSED PYRIDINE DERIVATIVES Eisai Co., Ltd. (JP) 2000-07-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020013460-A1 Condensed pyridine compound MUSK, HTR1A, PAX3 ALDH1A1 2989/4885CYP1A2 2126/4885LMNA 1057/4885
US-20040204421-A1 Certain 1,3-disubstituted isoquinoline derivatives MUSK, HTR1A, RYR1 ALDH1A1 1071/4885CYP1A2 1489/4885LMNA 1917/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.